Source comparison
CJC-1295 No DAC vs MK-677: Research Application Comparison
Mechanism GHRH receptor agonist. Amplifies endogenous GH pulses Ghrelin receptor agonist. Stimulates continuous GH secretion CJC preserves physiological rhythms; MK-677 overrides them Half-Life ~30 minutes (clears within 2–4 hours) 4–6 hours (IGF-1 elevation p
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist. Amplifies endogenous GH pulses
- Ghrelin receptor agonist. Stimulates continuous GH secretion
- CJC preserves physiological rhythms; MK-677 overrides them
- Half-Life
- ~30 minutes (clears within 2–4 hours)
- 4–6 hours (IGF-1 elevation persists 24+ hours)
- CJC requires precise timing; MK-677 allows once-daily dosing
- GH Pattern
- 2–10× amplification of existing pulses, returns to baseline
- Sustained elevation with flattened pulsatility
- CJC suits acute pulse studies; MK-677 suits chronic exposure models
- IGF-1 Effect
- Transient elevation during pulse, no cumulative buildup
- Cumulative elevation sustained above baseline
- MK-677 produces anabolic signaling CJC cannot match with single daily dose
- Administration
- Subcutaneous injection, 1–3× daily, timed to endogenous pulses
- Oral, once daily, no timing constraints
- MK-677 has significantly lower protocol burden
- Side Effects
- Transient hyperglycemia post-pulse, injection site reactions
- Sustained appetite increase, water retention, mild insulin resistance over time
- CJC's effects resolve between doses; MK-677's accumulate
- Research Suitability
- Acute GH dynamics, pulse modulation, feedback sensitivity studies
- Chronic anabolic signaling, sarcopenia models, prolonged IGF-1 elevation
- Match mechanism to experimental question. They are not interchangeable